BLFS BioLife Solutions, Inc.
Healthcare$24.03+0.33%ClosedMarket Cap: $1.17B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.12
P/S
11.73
EV/EBITDA
-155.79
DCF Value
$-4.53
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.9%
Operating Margin
-10.9%
Net Margin
-10.5%
ROE
-2.9%
ROA
-2.6%
ROIC
-2.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $27.5M | 63.3% | $27.0K | $1.2M | $— | — |
| Q4 null | $18.8M | 67.5% | $5.8M | $3.5M | $— | — |
| FY null | $96.2M | 64.6% | $-12.1M | $-12.1M | $— | — |
| Q3 null | $28.1M | 61.4% | $-89.0K | $621.0K | $— | — |
| Q2 null | $25.4M | 64.6% | $-16.6M | $-15.8M | $— | — |
| Q1 null | $23.9M | 65.9% | $-1.2M | $-448.0K | $— | — |
| Q4 null | $-3.4M | -241.6% | $1.4M | $12.5M | $— | — |
| FY null | $82.3M | 65.3% | $-7.1M | $-20.2M | $— | — |
| Q3 null | $30.6M | 71.3% | $-1.6M | $-1.7M | $— | — |
| Q2 null | $19.7M | 67.0% | $-3.7M | $-20.7M | $— | — |
| Q1 null | $18.4M | 66.4% | $-3.3M | $-10.2M | $— | — |
| Q4 2023 | $17.4M | 52.1% | $-7.5M | $-13.4M | $-0.30 | — |